News Release



Japan Credit Rating Agency, Ltd.

25-D-1306 December 23, 2025

Japan Credit Rating Agency, Ltd. (JCR) announces the following credit rating.

Medical Corporation KEIAIKAI (security code: -)

<Affirmation>

Long-term Issuer Rating: A-Outlook: Stable

Rationale

- (1) Medical Corporation KEIAIKAI ("KEIAIKAI") is a medical corporation operating four hospitals in Tamba City, Sanda City and Nishinomiya City in Hyogo Prefecture. KEIAIKAI is one of the largest medical corporations in the prefecture focusing on medical services for the chronic stage, with a total of 1,156 beds (60 for general acute care, 51 for rehabilitation in the convalescent phase, and 1,045 for recuperation). Other than these, it operates four long-term care health facilities (507 beds in total), group homes, and day care rehabilitation centers. The group has all the facilities in Hyogo Prefecture, providing community-based services, and established a management system capable of efficient operation by taking advantage of the business scale. In 2023, Minimally Invasive Treatment Department specializing in laparoscopy and endoscopy was established at Nishinomiya Keiaikai Hospital.
- (2) Stable business operations are expected to continue in the future. The management environment for medical institutions is extremely tough, as it becomes increasingly difficult to attract patients while various expenses are rising. In KEIAIKAI, each facility strives to secure patients and users, as well as to increase revenue, while thoroughly managing expenditures. Nishinomiya Keiaikai Hospital's Minimally Invasive Treatment Department is also operating at a high usage rate, and the cash flow is expected to remain stable going forward. In addition, it has minimal borrowings and surplus funds on hand, maintaining a sound financial position. Based on the above, JCR has affirmed the ratings on KEIAIKAI and retained the Stable outlook.
- (3) Although there are shortages in some positions, efforts are being made to secure and retain personnel, and there has been no significant impact on facility operations. The main long-term medical care ward has a relatively high occupancy rate thanks to its strengths in accepting seriously ill patients and providing end-of-life care. However, in recent years, with a trend toward shorter average hospital stays, it has become increasingly difficult to keep all beds constantly occupied, making it more important to secure new inpatients through further strengthening regional cooperation. At Minimally Invasive Treatment Department of Nishinomiya Keiaikai Hospital, the monthly number of cases has been steadily increasing, and it is considered to be developing as a new source of revenue.
- (4) Among medical institutions mainly specializing in chronic care, a relatively strong earning capacity has been maintained. However, while medical revenue has stagnated, personnel expenses and other costs have risen, resulting in lower operating profit from medical services in the fiscal year ended March 2025 compared to the previous fiscal year. In order to maintain a sound income and expenditure structure, both the changes in the medical service fee schedule for the fiscal year 2026 and how KEIAIKAI respond to this will be key points of attention. In terms of finances, net assets and cash on hand have increased thanks to stable business performance, and the financial structure is on an improving trend. No large-scale investments are planned for the time being, and KEIAIKAI is assumed to be able to maintain the strong financial base going forward.

Shigenobu Tonomura, Yosuke Sato

Rating

Issuer: Medical Corporation KEIAIKAI

<Affirmation>

Long-term Issuer Rating: A- Outlook: Stable



Rating Assignment Date: December 18, 2025

The assumptions for the credit ratings and the definitions of the rating symbols are published as "Types of Credit Ratings and Definitions of Rating Symbols" (January 6, 2014) in Information about JCR Ratings on JCR's website (https://www.jcr.co.jp/en/).

Outline of the rating methodology is shown as "JCR's Rating Methodology" (October 1, 2024) and "Medical Institutions" (August 1, 2023) in Information about JCR Ratings on JCR's website (https://www.jcr.co.jp/en/)..

The rating stakeholder participated in the rating process of the aforementioned credit ratings.

Japan Credit Rating Agency, Ltd.

Jiji Press Building, 5-15-8 Ginza, Chuo-ku, Tokyo 104-0061, Japan Tel. +81 3 3544 7013, Fax. +81 3 3544 7026

Information herein has been obtained by JCR from the issuers and other sources believed to be accurate and reliable. However, because of the possibility of human or mechanical error as well as other factors, JCR makes no representation or warranty, express or implied, as to accuracy, results, adequacy, timeliness, completeness or merchantability, or fitness for any particular purpose, with respect to any such information, and is not responsible for any errors or omissions, or for results obtained from the use of such information. Under no circumstances will JCR be liable for any special, indirect, incidental or consequential damages of any kind caused by the use of any such information, including but not limited to, lost opportunity or lost money, whether in contract, tort, strict liability or otherwise, and whether such damages are foreseeable or unforesceable. JCR's ratings and credit assessments are statements of JCR's current and comprehensive opinion regarding redemption possibility, etc. of financial obligations assumed by the issuers or financial products, and not statements of opinion regarding any risk other lane credit risk, such as market liquidity risk or price fluctuation risk. JCR's ratings and credit assessments are statements of opinion, and not statements of fact as to credit risk decisions or recommendations regarding decisions to purchase, sell or hold any securities such as individual bonds or commercial paper. The ratings and credit assessments may be changed, suspended or withdrawn as a result of changes in or unavailability of information as well as other factors. JCR receives a rating fee paid by issuers for conducting rating services in principle. JCR retains all rights pertaining to this document, including JCR's rating data. Any reproduction, adaptation, alteration, etc. of this document, including such rating data, is prohibited, whether or not wholly or partly, without prior consent of JCR.

JCR is registered as a "Nationally Recognized Statistical Rating Organization" with the U.S. Securities and Exchange Commission with respect to the following four classes. (1) Financial institutions, brokers and dealers, (2) Insurance Companies, (3) Corporate Issuers, (4) Issuers of government securities, municipal securities and foreign government securities.

JCR publishes its press releases regarding the rating actions both in Japanese and in English on the same day. In case that it takes time to translate rating rationale, JCR may publicize the summary version, which will be replaced by the full translated version within three business days. (Regarding Structured Finance products, JCR only publicize the summary version in English.)